diabetic retinal edema exsudative diabetic retinopathy
Conditions
Interventions
Group 1: Posterior sub-Tenon injection of Triamcinolonacetonide (20 mg in 0,5
ml) followed after 1 month by Macula Grid Laser (Argon Green laser).
Group 2: Intravitreal injection of Triamcinolonacet
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age > 18 jaar Diabetes Mellitus I or II Clinically Significant macular Edema (
Exclusion criteria
Exclusion criteria: Mainly focal leakage from microaneurysms Mainly cystoid leakage Proliferative Diabetic Retinopathy Previous Macula Gridlaser Panretinal photocoagulation 22 mm Hg Glaucoma and/or steroïdresponder Age related macula degeneration, uveïtis Vitreomacular traction and/or macula pucker (fundoscopically and/or OCT) Macula ischaemia (enlargement or irregular foveal avascular zone and/or 6 clock hours of macular capillary nonperfusion on fluorescein angiography) Other ocular disease where intraocular surgery is needed. Chronic renal failure with need for dialysis or renal transplant Allergy for Triamcinolonacetonide
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in mean ETDRS visual acuity 6 months after Macula Grid Laser and change in macular thickness measured by OCT compared to the situation before treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in visual acuity. Subjective change in visual acuity. Laserenergy needed for minimal visible effect. Incidence of side effects as rise in intraocular pressure, cataract formation, endophthalmitis, retinal detachment. Amount of leakage on fluorescein angiography. | — |
Countries
Netherlands
Outcome results
None listed